# Phase 3 Safety and Efficacy Study of ART-123 in Subjects With Severe Sepsis and Coagulopathy

> **NCT01598831** · PHASE3 · COMPLETED · sponsor: **Asahi Kasei Pharma America Corporation** · enrollment: 816 (actual)

## Conditions studied

- Severe Sepsis
- Coagulopathy

## Interventions

- **DRUG:** ART-123
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01598831
- **Lead sponsor:** Asahi Kasei Pharma America Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10-29
- **Primary completion:** 2018-04-05
- **Final completion:** 2019-02-28
- **Target enrollment:** 816 (ACTUAL)
- **Last updated:** 2020-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01598831

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01598831, "Phase 3 Safety and Efficacy Study of ART-123 in Subjects With Severe Sepsis and Coagulopathy". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT01598831. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*